CLDX 17.38 (+3.15%)
US15117B2025BiotechnologyBiotechnology

Celldex Therapeutics (CLDX) Stock Highlights

17.38 | +3.15%
2025-04-03 04:25:43
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. Its pipeline products are Varlilumab, CDX-301, CDX-1140,CDX-0159/Anti-KIT Program, and CDX-527.

Statistics

Range Today
16.4 17.64
Volume Today 707.3K
Range 1 Year
16.75 47
Volume 1 Year 217.69M
Range 3 Year
16.75 53.18
Volume 3 Year 537.6M
Range 10 Year
1.5 454.2
Volume 10 Year 1.22B

Highlights

Market Capitalization 1.32B (small)
Floating Shares 61.13M
Current Price 17.38
Price To Earnings -8.09
Price To Revenue 85.69
Price To Book 1.77
Earnings Per Share -2.45
Payout Ratio 0%

Performance

Latest +3.15%
1 Month -18.29%
3 Months -31.95%
6 Months -45.72%
1 Year -57.24%
3 Years -49.11%
5 Years +1014.1%
10 Years -95.71%

Benchmarks


Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.